after joining the study, a consent form is signed and a series of baseline tests are performed. these include medical history review, physical examination, blood tests, and a bone‑marrow sample to measure minimal residual disease (mr d), which indicates how many cancer cells remain.

the bone‑marrow test looks for cancer‑related genetic markers at a sensitivity of at least 10⁻⁴.

if the disease shows signs of progressing while the personalized cell product is being prepared, a short course of additional chemotherapy may be given. this is called bridging therapy and is intended to keep the disease stable until the obecel infusion can be performed.

a short chemotherapy regimen is administered to reduce the number of normal immune cells. this creates space for the infused obecel cells to expand. the regimen is given over several days according to the study protocol.

the personalized cell product, called obecel, consists of autologous enriched t cells that have been genetically modified to target cd19 and cd22. a single dose of 310,000,000 cells is delivered by intravenous infusion.

the infusion is performed in a controlled clinical setting and lasts for the time required to deliver the full cell dose.

following the infusion, the patient remains in the hospital for close observation. vital signs, blood tests, and neurological status are checked regularly to detect any signs of cytokine release syndrome (c rs) or immune effector cell‑associated neurotoxicity syndrome (i cans).

the total number of hospital days starts with the lymphodepletion regimen and continues until the medical team determines that the patient is stable.

approximately 28 days after the obecel infusion, a follow‑up visit is scheduled. blood and bone‑marrow samples are taken to assess mr d response and to evaluate any adverse events.

the results indicate the early effectiveness of the treatment and guide further care.

around three months (about 90 days) after the infusion, another assessment is performed. the primary goal is to determine the mr d complete response rate, meaning the proportion of patients whose bone‑marrow test shows no detectable disease.

additional laboratory tests, including immunoglobulin levels, are measured at this time.

the patient attends scheduled visits at defined intervals (for example, every few months) until at least 24 months after the infusion. each visit includes physical examination, blood work, and bone‑marrow testing to monitor the durability of the mr d response.

measurements of B‑cell numbers, immunoglobulin levels, and any need for intravenous immunoglobulin (ivig) replacement are recorded.

any occurrence of disease relapse, new malignancy, or additional therapy such as allogeneic stem‑cell transplant is documented.

if the treating physician determines that a second infusion is necessary, the timing and reason for the delay are recorded. the second dose follows the same dosing and administration procedure as the first infusion.

at the end of the study period, a final assessment is performed to evaluate long‑term outcomes such as event‑free survival, overall survival, and any late adverse events.

all collected data are analyzed to determine the overall efficacy and safety of obecel in patients with minimal residual disease.